SCHEMBL6561724

SCHEMBL6561724

CC(CNS(=O)(=O)C(C)C)c1ccc(CCCNC(=O)OCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 6/20 0.51
GRIA2 P42262 1/20 0.49
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48
HTT P42858 1/20 0.48
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 1/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6562867 0.94 GRIA4 (0.55) GRIA4GRIA2HTTMAPTL3MBTL1
SCHEMBL6563108 0.84 CA1 (0.50) GRIA4GRIA2HTTMMP2MMP9
SCHEMBL6748819 0.80 HTT (0.72) CHRNB2CHRNB4CHRNA3CHRNA4HTT
SCHEMBL6563273 0.78 GRIA4 (0.67) GRIA4GRIA2
SCHEMBL13895513 0.78 HTT (0.74) CHRNB2CHRNB4CHRNA3CHRNA4HTT
SCHEMBL7276818 0.76 HTT (0.67) CHRNB2CHRNB4CHRNA3CHRNA4HTT
SCHEMBL6565213 0.75 GRIA4 (0.79) GRIA4GRIA2
SCHEMBL5877953 0.75 GRIA4 (0.64) GRIA4GRIA2MMP2MMP9CA2
SCHEMBL6715818 0.75 HTT (0.65) CHRNB2CHRNB4CHRNA3CHRNA4HTT
SCHEMBL13073762 0.75 LMNA (0.55) HTTSMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 GRIA4 17/4885GRIA2 8/4885CHRNB2 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.